

RESEARCH ARTICLE

A Novel Approach to Cloning and Expression of Human Thymidylate Synthase

Ying-Tao Lv, Pei-Juan Du, Qiao-Yan Wang, Yuan Tan, Zong-Bin Sun, Zhong-Liang Su, Cong-Min Kang*

Abstract

Thymidylate synthase (TS) catalyzes the transfer of a methyl group from methylenetetrahydrofolate to dUMP to form dTMP. It is a primary target in the chemotherapy of colorectal cancers and some other neoplasms. In order to obtain pure protein for analysis of structure and biological function, an expression vector TS-pET28b (+) was constructed by inserting wild-type human thymidylate synthase (hTS) cDNA into pET28b (+). Then an expression strain was selected after transformation of the recombinant plasmid into Rosetta (DE3). Fusion protein with His-tag was efficiently expressed in the form of inclusion bodies after IPTG induction and the content was approximately 40.0% of total bacteria proteins after optimizing expression conditions. When inclusion bodies were washed, dissolved and purified by Ni-NTA under denatured conditions, the purity was up to 90%. On SDS-PAGE and West-blotting, the protein band was found to match well with the predicted relative molecular mass-36kDa. Bioactivity was 0.1 U/mg. The results indicated that high-level expression of wild-type hTS cDNA can be achieved in prokaryotes with our novel method, facilitating research into related chemotherapy.

Keywords: Wild - type human thymidylate synthase cDNA - prokaryotic expression - rare codon

Asian Pac J Cancer Prev, **14** (12), 7523-7527

Introduction

Thymidylate synthase (TS, E 2.1.1.45), consisting of two identical subunits with molecular weight of 36.0kDa, catalyzes the reductive methylation of dUMP to produce dTMP (Carrers et al., 1995). This process is the only de novo source of dTMP, which is subsequently metabolised to thymidine triphosphate (dTTP), exclusively for incorporation into DNA during synthesis and repair (Ackland et al., 2006). In the rapid proliferative cells, it can result in apoptosis to decrease the level of TS. This phenomenon is exploited in therapeutic protocols utilizing TS inhibitors, such as raltitrexed, pemetrexed, or prodrugs such as 5-fluorouracil and 5-fluorodeoxyuridine that are metabolized to TS inhibitors. Two antifolates, Raltitrexed and Pemetrexed, are licensed anticancer drugs. Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. Other antifolate TS inhibitors, currently tested in clinical studies, that show encouraging anticancer activities are Plevitrexed, GW7904L and Nolatrexed. A new prospect among antifolates, demonstrating a very desirable pattern of pharmacological properties, is BGC 945 that showed promising antitumor activities and has been nominated for clinical development (Gibson et al., 2011). In order

to exploit new TS inhibitors, it's important to study the structure and properties of TS and also the crystal structures of hTS. It is reported that a new crystal form of human TS (hTS) which allows binding studies by soaking crystals in artificial mother liquors containing ligands that bind in the active site. Using this approach, crystal structures of hTS complexes with FdUMP and dUMP were obtained, indicating that this form should facilitate in high-throughput analysis of hTS complexes with drug candidates. Crystal soaking experiments using oxidized glutathione revealed that hTS binds this ligand (Jarmula 2010).

Steadman et al. (1998) utilized site-directed mutagenesis to create 12 mutant proteins with substitutions at residue 216. The result proved that a serine residue corresponding to Ser216 in human TS is an essential site to binding dUMP. Phan et al. (2001) found that TS functions as an RNA binding protein that regulates the expression of its own mRNA translation, the emergence of resistance to the treatment is often related to the increased level of TS in cancer cells, which have been linked to the elimination of TS binding to its own mRNA upon drug binding. During the early stage, TS was obtained from human cells (Lockshin et al., 1979; Dolnick et al., 1977). With the development of gene recombination and prokaryotic expression system, it is feasible to expression human TS in *E. coli*. Davisson et al. (1989) isolated a full-length cDNA

clone of human TS and firstly expressed it in *Escherichia coli*. Since wild-type human TS cDNA is eukaryote gene (Joan et al., 1997), and have many rare codons of *E. coli*, the yield of this enzyme was only 1.6% of the *E. coli* protein. Joan (Hori et al., 1990) converted purine bases in the third, fourth, and fifth codons of the TS cDNA to thymine, without altering the encoded protein product, which helped to lighten the effect of rare codon on the expression level in *E. coli*, and the yields of this enzyme could be improved to 25%-30% of the *E. coli* protein.

Although site-directed mutagenesis can help to lighten the effect of rare codon on the expression level in *E. coli*, that needs large amount of experimental operations. In this paper, we describe a novel method for improving the expression of wild-type human TS cDNA in *E. coli*. In the experiment, wild-type TS gene was cloned into expression vector pET-28b (+), and respectively transformed into expression host BL21 (DE3) and Rosseta (DE3), which has been added the rare codons of *E. coli*. The results showed that the yields of TS in Rosseta (DE3) was more than the BL21 (DE3). By optimizing the expression conditions, the yields of TS in Rosseta (DE3) was up to about 40% of the *E. coli* protein.

Materials and Methods

Enzymes and chemicals

DNA polymerase, restriction enzymes, and T4 DNA ligase were purchased from TaKaRa Biotechnology (Dalian, China). All other chemicals were from Sigma.

Bacterial strains, plasmids and culture medium

Escherichia coli DH5 α was utilized for subcloning propagation of plasmids, BL21 (DE3) (Meck, China) and Rosetta (DE3) (Meck, China) was utilized for host of gene expression. pMD18-T (TaKaRa, Dalian) and pET-28b (+) (Meck, China) were respectively used for subclone vector and expression vector. pcDNA3.1zeo-TS was gifted by Dr. Maria Zajac-Kaye (Basic Research Laboratory and Molecular Therapeutic Program, National Institute of Health). The strains were maintained on LB agar plates and grown at 37 °C unless otherwise.

DNA manipulations

All cloning techniques including PCR, restriction digestion, ligation, *E. coli* transformation, DNA preparation were described previously (Sambrook et al., 1989).

Construction of subclone vector for amplification of human TS cDNA

According to the sequence of TS gene (GenBank ID: NM_001071), The primers were designed as the following, upstream primer: 5'-ATCAT ATGTA CCGCG CCATG CCTGT G-3' (NdeI) and downstream primer: 5'-GCCTC GAGAA CCCTA AACAG CCATT TCCAT TT-3' (XhoI). The PCR product was purified by DNA gel extraction kit (Sangon, Shanghai). Specific fragments about 1kb were connected to pMD18-T vector, then transformed into competence cells of *E. coli* DH5 α . By blue-white spot screening, identification of plasmid PCR (Figure 1), the positive strain was sequenced in

the DNA sequencing department of Biosune systems Biology, Shanghai. The subclone vector was named as TS-pMD18-T (Figure 1A).

Construction of E. coli expression vector for synthesis of human TS

The full length of human TS cDNA in TS-pMD18-T was isolated by a double digestion of NdeI, XhoI and cloned into the multiple cloning site (MCS) downstream of the expression vector pET-28b (+) that was previously digested with the same two enzymes. The recombinant plasmid was transformed into *E. coli* DH5 α , identified by PCR, double enzymes digestion (Figure 3) and named TS-pET-28b (+) (Figure 1B).

Expression and expression form analysis of recombinant human TS

E. coli BL21 (DE3) and Rosetta (DE3) with TS-pET-28b (+) was activated in LB broth, containing 50 μ g/ml kanamycin, and 34 μ g/ml chloromycetin at 37°C with 200 rpm shaking. 500 μ l of activated culture was transferred into 10ml of fresh LB broth with the mentioned antibiotics under the same condition for about 1h. When OD600 reached 0.5-0.7, IPTG (final concentration = 1.5 mM) was added to induce the synthesis of human TS. After 8h of induction at 37°C, *E. coli* was harvested by 15min of centrifugation at 8000 rpm and resuspended in 3 mL of buffer A (50 mM phosphate buffer, pH 8.0). The samples were taken out and analyzed by 15% SDS-PAGE (Figure 4 A), The rest were sonicated (50 cycles with 10s on/15s off) in ice using a sonicator JY92-11 system (Scientz Biotechnology Co, Ltd, Ningbo) and then centrifuged at 13000rpm for 15min. The supernatant and resuspended precipitation were analyzed by 15% SDS-PAGE (Figure 4a) and West-blotting.

Purification and refolding of recombinant human TS with 6 \times His-tag

Because there is 6 \times His oligonucleotide sequence between the promoter and MCS, human TS had a 6 \times His-tag in the N-terminal. A nickel affinity column was utilized for purification of the recombinant human TS.

About 200 ml of culture broth was centrifuged at 8000rpm for 15 min, and cells were resuspended in Buffer B (8M urine, 100 mM NaH₂PO₄, 100 mM Tris-HCl, pH 8.0). The cells were lysed by ultrasonication (20 times, 5S \times 5S) for further purification and then filtered through 0.45 μ m microporous membrane. The filtrate was chromatographed on Ni-NTA Superflow Cartridge (1ml, QIAGEN in China), which was preequilibrated with bufferB. After it was washed with the same buffer, the recombinant human TS was respectively eluted with 10 volumes of buffer B containing 200mM imidazole (Figure 5). The elution buffer was assayed protein concentration by Bradford method and dialysed with 20 mM Tris-HCl, 2 mM EDTA, 0.1% PEG, 0-6 M urine, 0.1 mM GSSG, 0.2 mM GSH, pH7.4, 0.025 mg/ml Protein under 4°C.

Bioactivity assay of recombinant human TS

Bioactivity assay was carried out on the basis of Williams's method (Steadman et al., 1998). Enzyme




Figure 1. Construction of Subclone Vector and Expression Vector




Figure 2. PCR Identification of TS-pMD18-T. M: DNA Marker E, 1: The PCR product of TS-pMD18-T

activity was measured at 37°C, The purified enzyme was incubated in Morrison buffer (Ellis and Morrison 1982) containing 1mM dUMP and 150 μ M (6R)-CH₂H₄folate. The absorbance change at 340nm due to the conversion of CH₂H₄folate to H₂folate ($\epsilon_{340}=6.4 \text{ mM}^{-1}\text{cm}^{-1}$ (Wahba et al., 1961) was monitored for 1-10min. One unit of enzyme activity is defined as the amount of enzyme required to synthesize 1 μ mol of dTMP per minute under these conditions.

Results

The subclone and expression vector construction of human TS cDNA

After constructed the subclone vector TS-pMD18-T, we carried on preliminary identification using PCR. The product was analyzed by 1% agarose gel electrophoresis, and the result showed that there was a band about 1kb (Figure 1), proved human TS cDNA had insert into pMD18-T. We sent DH5 α with TS-pMD18-T to sequence analysis; The result showed that there was no nucleotide mutation.

Since TS-pET-28b (+) contain NdeI, XhoI site. We digested it with NdeI, XhoI (Figure 3a), and identified with PCR (Figure 3b). The result of restriction enzyme




Figure 3. The Identification of TS-pET-28b(+). (a) PCR analysis of the recombinant expression vector--TS-pET-28b(+). M: Marker E. 1: The PCR product of TS-pET-28b(+). (b) Restriction enzyme analysis of the recombinant expression vector--TS-pET-28b(+). M1: 1kb ladder marker, 1: TS-pET-28b(+) digested by Nde I, 2: TS-pET-28b(+) digested by Xho I, 3: TS-pET-28b(+) digested by Nde I and Xho I, M2: Marker E




Figure 4. SDS-PAGE Analysis of the Expression of Human TS. (a) SDS-PAGE analysis of the expression of human TS. M: Protein molecular mass marker, 1: Rosetta(DE3), 2: pET-28b(+)/Rosetta (DE3) induced by IPTG, 3: The non-induced TS-pET-28b(+)/Rosetta(DE3), 4: TS-pET-28b(+)/Rosetta(DE3) before induced by IPTG, 5: TS-pET-28b(+)/Rosetta(DE3) induced by IPTG. (b) Location of TS expressing in Rosetta(DE3). M: Protein molecular mass marker, 1: Rosetta(DE3), 2: TS-pET-28b(+)/Rosetta (DE3) induced by IPTG, 3: The precipitation of TS-pET-28b(+)/Rosetta(DE3) by high-speed centrifugation, 4: The supernatant of TS-pET-28b(+)/Rosetta(DE3) by high-speed centrifugation

digesting showed that there were two DNA bands about 1kb, 5kb, which were similar as human TS cDNA and pET-28b (+). Expression vector construction of human TS cDNA was constructed.

Expression of human TS in *E. coli*

TS-pET-28b (+)/BL21 (DE3) and TS-pET-28b (+)/Rosetta (DE3) were respectively induced under 37°C, The OD600 of the cultures grown under IPTG induction for 16h were all about 1.5, which was about two fold less than the values shown by the non-induced TS-pET-28b (+)/BL21 (DE3) and TS-pET-28b (+)/Rosetta (DE3) or the pET-28b (+)/BL21 (DE3) pET-28b (+)/Rosetta (DE3) (both induced and non-induced) grown for the same duration, respectively. The lower absorption from the induced TS-pET-28b (+)/BL21 (DE3) and a TS-pET-28b (+)/Rosetta (DE3) cultures suggested that the cultures were expressing recombinant human TS, and the expression of recombinant proteins may retard the cell growth and result in lower absorption.

When total cells of TS-pET-28b (+)/BL21 (DE3) and TS-pET-28b (+)/Rosetta (DE3) after inducing were analyzed by SDS-PAGE (Figure 4a) and West-blotting


Table 1. The Change of A340 Followed by the Reaction Time

Results	Reaction time (min)									
	1	2	3	4	5	6	7	8	9	10
A340 (1)	0.068	0.081	0.098	0.11	0.126	0.139	0.155	0.17	0.182	0.199
A340 (2)	0.07	0.085	0.098	0.114	0.128	0.143	0.157	0.17	0.188	0.199
Average of A340	0.069	0.083	0.098	0.112	0.127	0.141	0.156	0.17	0.185	0.199
The amount of dTMP (μmol)	0.069	0.085	0.102	0.113	0.127	0.142	0.156	0.171	0.186	0.198

Table 2. The Rare Codon Analysis of Human TS cDNA

Amino acid	Rare codons	Codon usage frequency in <i>E. coli</i> (x/1000)	Location in human TS cDNA	Percentage in TS cDNA (%)
Arg	AGG	2.1	151, 433, 853	0.91
	AGA	2.4	217, 391, 454, 502, 538, 541, 568, 658, 835	2.7
	CGA	2.4	358, 826, 862	0.91
Leu	CTA	3.98		0
	CTC	10.6	121, 592, 661, 697, 835	1.5
Pro	CCC	2.4	34, 40, 43, 817	0.91
Gly	GGA	8.2	280, 313, 337, 364, 463, 469, 649, 757	2.4
Total		32		9.7

The codon usage frequency in *Escherichia coli* B [gbcbct]: 11 originates from GenBank Codon Usage Database

**Figure 5. Preliminary Purification of Recombinant TS.**

1: Cleared cell lysate, 2: Flow-through fraction, 3: Wash fraction, 4: Elution fraction containing 100 mM imidazole, 5: Elution fraction containing 150 mM imidazole, 6: Elution fraction containing 150 mM imidazole, 7: Elution fraction containing 150 mM imidazole, M: Protein molecular mass marker

(Figure 4b), there was a significantly protein band on the TS-pET-28b (+)/Rosetta (DE3) track at 36.0kDa which matched well with human TS relative molecular mass (Carrers et al., 1995), however, the TS-pET-28b (+)/BL21 (DE3) was not significantly. The reason is that human TS gene has many *E. coli* rare codons, and *E. coli* rare codons have significant effect on the expression of human TS (Hori et al., 1990; Joan et al., 1997). Rosetta (DE3) has T7-promoter and have added the rare codon tRNA. In order to lighten the effect of rare codon to the expression of human TS, we selected Rosetta (DE3) as the expression host. By location analysis (Figure 4b), human TS expressing in Rosetta (DE3) was mainly on inclusion body.

Purification and refolding of recombinant human TS with 6xHis-tag

Human TS was found to be expressed in Rosetta

(DE3) as inclusion bodies from the SDS-PAGE analysis (Figure 4b). Attempts to solubilize human TS from these pellets with Buffer B failed, unless cells were lysed by ultrasonication. Human TS became soluble under these conditions and could be subjected to further purification using Ni-NTA cartridge. The use of successive stepwise elution on the gel allowed the best elution (Buffer B containing 200mM imidazole) and finally purification of protein to 89% (Figure 5).

Bioactivity assay of recombinant human TS

Under room temperature conditions, determination of enzyme activity employed ultraviolet spectrophotometry. Experimental results see Table 1. The linear equations obtained is $Y=0.0145X+0.054$ ($R=99.98\%$), including the reaction time X and the amount of the resultant dTMP Y. Then the specific activity of human TS after renaturation calculated was $SP=0.0186/0.15=0.124$ U/mg (protein concentration was 0.15 mg/ml). The result is similar with the standard specific activity of human TS (Steadman 1998).

Discussion

In the early stage of this experiment, we transformed TS-pET-28b (+) into the general expression host BL21 (DE3), the result (Figure 4a) showed that the yield of human TS was low. We thought that the conditions (temperature, inducing time, and IPTG concentration) may be not the optimal, and carried out the orthogonal experiments to optimizing the expression conditions. But the expression level was never improved. We thought the reason may be that codon preference in *E. coli* and eukaryotic organisms is different, and exists many rare codon of *E. coli* in human TS cDNA. Grosjean (Zhang et al., 1989) found that there are eight types rare codons (AGA, AGC, AUA, CCG, CCT, CTC, CGA, et al), and lack of corresponding tRNA in *E. coli*. Kane (Fu et al., 2007) proved the codons (CUA, CGA, CCC, GGA) had

negative effect on the expression of eukaryotic gene in *E. coli*. When the rare codons occurs continuously, the expression will be inhibited, sometimes even be terminated. By site-directed mutagenesis converting the rare codon to high-frequency codon, it can help to lighten the effect of rare codon on the expression level in *E. coli* (Joan et al., 1997; Liu et al., 2007). The other way to improve the yield is to add the rare codon tRNA to the expression host (Fu et al., 2007; Liu et al., 2007).

TS gene is eukaryote gene (Davisson et al., 1989). By analysis to wild-type human TS cDNA, there are many rare codon of *E. coli* (Table 2). Rosetta (DE3) contains six rare codon tRNA (AUA, AGG, AGA, CUA, CCC and GGA), which is expressed by a plasmid compatible with pET vectors. Afterwards, we transformed TS-pET-28b (+) into Rosetta (DE3). By SDS-PAGE analysis (Figure 4a), it's very obvious that the expression level of human TS in Rosetta (DE3) is more than the BL21 (DE3). By orthogonal experiments to optimizing the expression conditions, the yield is up to 40% of the *E. coli* protein.

In summary, rare condon has important influence on the expression of human TS in *E. coli*. By adding the rare codon tRNA, the yield is improved. Human TS is high expressed by a novel method.

Acknowledgements

This research is supported by the National Natural Science Foundation of China (grant numbers 21072111 and 21272131).

References

- Ackland SP, Clarke SJ, Beale P, et al (2006). Thymidylate synthase inhibitors. *Update Cancer Ther*, **1**, 403-27.
- Carrers CW, Santi DV (1995). The catalytic mechanism and structure of thymidylate synthase. *Annu Rev Biochem*, **64**, 721-62.
- Davisson VJ, Sirawaraporn W, Santi DV (1989). Expression of human thymidylate synthase in *Escherichia coli*. *J Biol Chem*, **264**, 9145-8.
- Dolnick BJ, Cheng Y (1977). Human thymidylate synthetase derived from blast cells of patients with acturemyelocyticleukemia. Purification and characterization. *J Biol Chem*, **252**, 7697-703.
- Ellis KJ, Morrison JF (1982). Buffers of constant ionic strength for studying pH-dependent processes. *Methods Enzymol*, **87**, 405-26.
- Fu W, Lin J, Cen P (2007). 5-Aminolevulinic acid production with recombinant *Escherichia coli* using a rare codon optimizer host strain. *Appl Microbiol Biotechnol*, **75**, 777-82.
- Gibson LM, Celeste LR, Lovelace LL, et al (2011). Structures of human thymidylate synthase R163K with dUMP, FdUMP and glutathione show asymmetric ligand binding. *Biological Crystallography*, **1**, 60-6.
- Hori T, Takahashi E, Ayusawa D, et al (1990). Regional assignment of the human thymidylate synthase (TS) gene to chromosome band by non-isotopic in situ hybridization. *Hum Genet*, **85**, 576-80.
- Jarmula A (2010). Antifolate inhibitors of thymidylate synthase as anticancer drugs. *Mini-Rev Med Chem*, **10**, 1211-22.
- Joan PL, Maley GF, Chu E, et al (1997). High-level expression of human thymidylate synthase. *Protein Expression Purif*, **10**, 256-62.

- Lockshin A, Moran RG, Danenberg PV (1979). Thymidylate synthetase purified to homogeneity from human leukemic cells. *Proc Natl Acad Sci*, **76**, 750-4.
- Liu J, Hu T, Hou X (2007). High-level expression of functional tumor suppressor LKB1 in *Escherichia coli*. *Acta Biochim Biophys Sin*, **39**, 779-86.
- Phan J, Steadman DJ, Koli S, et al (2001). Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors. *J Biol Chem*, **276**, 14170-7.
- Sambrook J, Fritsch EF, Maniatis T (1989). *Molecular Cloning: A Laboratory Manual*. 2ed New York: Cold Spring Harbor Laboratory.
- Steadman DJ, Zhao PS, Spencer HT, et al (1998). A structural role for glutamine 214 in human thymidylate synthase. *Biochemistry*, **37**, 7089-95.
- Wahba AJ, Friedkin M (1961). Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. *Biol Chem*, **236**, 11-2.
- Zhang H, Cisneros RJ, Dunlap RB, et al (1989). Efficient synthesis of mouse thymidylate synthase in *Escherichia coli*. *Gene*, **84**, 487-91.